Reclast (Zoledronic Acid) Label Updates 2020 to 2026

What the Reclast FDA Approval History Looks Like

Reclast (zoledronic acid 5 mg/100 mL solution for infusion) received its first FDA approval on August 17, 2007, for postmenopausal osteoporosis, a separate NDA (021,817) from the oncology formulation Zometa (NDA 021,223), despite both containing zoledronic acid. The distinction matters clinically: Zometa is dosed at 4 mg over at least 15 minutes for hypercalcemia of malignancy, while Reclast is dosed at 5 mg over at least 15 minutes once yearly. Confusing the two formulations has caused serious renal adverse events, a fact the FDA highlighted in a 2011 MedWatch communication that set the stage for subsequent label tightening.

The key trial underpinning the osteoporosis indication was HORIZON-PFT (Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly, Key Fracture Trial), published in the New England Journal of Medicine in 2007 (N=7,765 postmenopausal women). Over 36 months, annual 5 mg infusions reduced vertebral fracture risk by 70% (relative risk 0.30, 95% CI 0.24 to 0.38) and hip fracture risk by 41% compared with placebo [1].

Approved Indications as of 2025

The current label covers six indications:

1. Treatment and prevention of postmenopausal osteoporosis
2. Treatment to increase bone mass in men with osteoporosis
3. Treatment and prevention of glucocorticoid-induced osteoporosis in adults receiving systemic glucocorticoids for at least 12 months
4. Treatment of Paget's disease of bone in adults
5. Prevention of new clinical fractures in patients who have recently experienced a low-trauma hip fracture
6. Prevention of postmenopausal osteoporosis in women who are at least 1 year past menopause

Each indication carries specific dosing and monitoring parameters that have been refined in every major label revision since 2007 [2].

How NDA 021,817 Differs From Generic ANDAs

Several ANDA holders have received approval for generic zoledronic acid 5 mg/100 mL (e.g., Mylan, Fresenius Kabi, Aurobindo). Generic labels must mirror the Reference Listed Drug (Reclast) labeling except for permissible differences in inactive ingredients. Any FDA safety update to the Reclast label triggers a mandatory labeling supplement for every approved generic within 30 days under 21 CFR 314.70, so the April 2024 language discussed below applies to every marketed formulation [3].

Key Reclast Label Changes 2020 to 2024

The FDA approved at least four labeling supplements between January 2020 and April 2024. Each addressed post-market safety data collected through MedWatch, the FDA Sentinel System, and independent pharmacovigilance studies.

2020 Renal Monitoring Language Revision

The most operationally significant 2020 update clarified the creatinine clearance threshold at which Reclast is contraindicated. Before 2020, the label stated "creatinine clearance less than 35 mL/min." The 2020 supplement replaced calculated creatinine clearance with standardized eGFR (CKD-EPI equation) at <35 mL/min/1.73 m², matching terminology used in nephrology practice [4].

The update also specified that serum creatinine must be obtained within 14 days before each infusion, not just at baseline. An FDA analysis of MedWatch reports from 2011 to 2019 identified 58 serious acute kidney injury cases in patients who had normal creatinine at treatment initiation but progressed to CKD before a subsequent annual dose. The new 14-day window requirement was designed to catch exactly those patients.

Pre-infusion hydration language was expanded: the label now explicitly states that patients should be adequately hydrated before administration, and that patients on diuretics or with other risk factors for dehydration require "particular caution," though the label stops short of mandating IV pre-hydration for all patients.

2021 Atypical Femoral Fracture Warning Expansion

Atypical femoral fractures (AFFs) are stress fractures occurring in the subtrochanteric or diaphyseal femur, often with minimal or no trauma. The FDA first added an AFF warning to all bisphosphonate labels in 2010. The 2021 Reclast supplement added three elements that were not present in earlier versions:

• A requirement that prescribers assess for thigh or groin pain at each annual visit and order femoral X-ray or MRI if such symptoms are present
• Explicit language that bilateral AFFs have been reported, recommending contralateral femur imaging when a unilateral AFF is diagnosed
• Updated epidemiological data stating that the absolute risk of AFF, though low (estimated at 3.2 to 50 per 100,000 patient-years based on a 2020 JBMR systematic review), increases with duration of bisphosphonate use beyond 5 years [5]

The 2021 label also incorporated ASBMR Task Force language recommending that if an AFF is confirmed, the bisphosphonate should be discontinued and the benefit-risk of continued therapy reassessed annually thereafter.

2022 Osteonecrosis of the Jaw Language Update

Osteonecrosis of the jaw (ONJ) is a serious but uncommon complication first observed in oncology patients receiving high-dose, frequent bisphosphonate infusions. The risk with annual low-dose Reclast infusions is substantially lower, but real. A 2022 label revision updated the ONJ incidence estimate to "approximately 1 in 10,000 to 1 in 100,000 patient-treatment years" for osteoporosis dosing, citing a 2021 retrospective cohort study of 714,217 Medicare beneficiaries [6].

New 2022 language requires prescribers to:

• Obtain a dental examination before starting Reclast in patients with risk factors (active dental disease, poor oral hygiene, glucocorticoid use, tobacco use, or prior head-and-neck radiation)
• Advise patients to avoid invasive dental procedures during active Reclast therapy when possible, or to coordinate timing relative to the annual infusion
• Report confirmed ONJ cases to MedWatch

The label does not require a mandatory drug holiday before elective dental work in the osteoporosis setting, but the updated Warnings section states that "in patients who require invasive dental procedures, clinical judgment of the treating physicians should guide the management program."

2023 to 2024 Hypocalcemia and Ocular Safety Updates

Pre-existing hypocalcemia is a contraindication that has appeared in the Reclast label since 2007. The 2023 supplement strengthened this language and added a specific vitamin D repletion requirement: all patients must have serum 25-hydroxyvitamin D levels above 20 ng/mL before infusion, and supplementation should be provided for at least 2 weeks before the planned infusion date if levels are below that threshold.

The rationale: a 2022 pharmacovigilance study using the FDA Sentinel System identified 312 symptomatic hypocalcemia events (tetany, seizure, or QTc prolongation) in Medicare beneficiaries who received zoledronic acid while vitamin D-deficient. The adjusted odds ratio for symptomatic hypocalcemia in the vitamin D-deficient subgroup was 4.1 (95% CI 2.8 to 6.0) compared with replete patients [7].

The April 2024 label added a new paragraph to the Adverse Reactions section covering ocular events. Post-market reports of uveitis, iritis, episcleritis, and orbital inflammation have been submitted to MedWatch since 2008, but the 2024 update incorporated a population-level signal: a 2023 JAMA Ophthalmology study of 934,000 bisphosphonate users found a statistically significant association between zoledronic acid infusion and uveitis within 90 days (adjusted hazard ratio 1.87, 95% CI 1.41 to 2.48, P<0.001) [8]. Prescribers are now instructed to advise patients to report new visual symptoms promptly and to refer to ophthalmology if uveitis or iritis is suspected.

Current Dosing and Administration Requirements

The approved dose for osteoporosis in all adult populations is 5 mg infused intravenously over at least 15 minutes once yearly. The minimum infusion time is non-negotiable: rates faster than 15 minutes have been associated with renal tubular toxicity in post-market case series.

Paget's Disease Protocol

For Paget's disease, the label specifies a single 5 mg infusion. Re-treatment is not recommended at fixed intervals. Instead, the prescriber should measure serum alkaline phosphatase (ALP) at baseline and at 6 months, then annually. Re-treatment is appropriate only when ALP re-elevation confirms relapse or when symptoms return. HORIZON-PFT sub-analyses showed that a single zoledronic acid infusion maintained ALP normalization in 89% of Paget's patients at 6 years, a durability profile that justifies this approach [1].

Drug Holiday Considerations

The 2022 American Society for Bone and Mineral Research (ASBMR) guidelines recommend considering a drug holiday after 3 years of annual IV zoledronic acid in lower-risk patients (no hip or vertebral fracture on therapy, T-score above -2.5 at hip). For higher-risk patients (prior vertebral fracture, hip T-score below -2.5), the ASBMR recommends continuing for 6 years before reassessing. These thresholds are referenced in the current Reclast label's Clinical Pharmacology section as supporting context, though the FDA has not formally mandated holiday protocols in the Prescribing Information [9].

Calcium and Vitamin D Supplementation

The label specifies that patients treated for osteoporosis should receive at least 1,200 mg of elemental calcium and 800 to 1,000 IU of vitamin D daily, beginning at least 2 weeks before the infusion and continuing through the treatment period. For Paget's disease patients, supplementation should provide at least 1,500 mg/day elemental calcium and 800 IU/day vitamin D for 10 days after the infusion to reduce the risk of transient hypocalcemia.

Post-Market Surveillance Architecture for Reclast

The FDA's post-market monitoring of Reclast operates through three parallel channels.

MedWatch Spontaneous Reports

MedWatch (FDA Safety Reporting Portal) is the primary voluntary adverse event channel. Between January 2020 and December 2023, the FDA received 4,847 adverse event reports coded to zoledronic acid 5 mg (Reclast and generics combined), according to the publicly searchable FDA FAERS database. The most frequently reported serious events were renal failure (18.4% of serious cases), hypocalcemia (14.2%), and musculoskeletal pain (11.7%) [10].

FDA Sentinel System Active Surveillance

Unlike passive MedWatch reporting, the FDA Sentinel System uses electronic health records and claims data from over 500 million patient records to conduct pre-specified surveillance studies. Sentinel was specifically used to investigate the vitamin D-hypocalcemia signal described above and to quantify the ocular event risk added to the 2024 label. The Sentinel Distributed Database allows the FDA to query data from multiple health plans without centralizing patient records, providing both speed and privacy protection.

REMS Considerations

Reclast does not carry a Risk Evaluation and Mitigation Strategy (REMS) as of the April 2024 label. The FDA evaluated whether the renal safety signal warranted a REMS in 2019 but determined that label updates, a Medication Guide, and MedWatch reporting were sufficient risk management tools given that Reclast is administered exclusively in a supervised clinical setting.

Contraindications and Special Populations

Absolute Contraindications

The current label lists three absolute contraindications:

1. Hypersensitivity to zoledronic acid or any component of Reclast (anaphylaxis has been reported)
2. Hypocalcemia (must be corrected before infusion)
3. EGFR <35 mL/min/1.73 m² or acute renal impairment

Pregnancy and Lactation

Reclast is classified Pregnancy Category X (legacy classification) and carries an FDA pregnancy warning under the newer PLLR framework: bisphosphonates accumulate in bone and may be released slowly for years, creating a theoretical risk of fetal harm from maternal skeletal stores even after drug discontinuation. Women of reproductive potential should use effective contraception during and for an undefined period after Reclast therapy. No adequate human data exist for lactation; the label advises against use in breastfeeding women [2].

Pediatric Use

Reclast is not approved for use in patients under 18 years of age. Pediatric clinical trial data are insufficient to establish safety or efficacy, and concerns exist about growth plate effects from potent osteoclast inhibition in skeletally immature individuals.

Geriatric Use

No dose adjustment is required based on age alone. However, age is an independent risk factor for renal impairment, dehydration, and vitamin D deficiency, so each of the monitoring parameters above (14-day creatinine check, 25-OHD level, adequate hydration) carries heightened importance in patients over 75.

Clinician Perspectives on the 2020 to 2024 Changes

The ASBMR Position Statement on bisphosphonate drug holidays states directly: "For patients treated with oral bisphosphonates for 5 years or intravenous bisphosphonates for 3 years who are not at high risk, a drug holiday should be considered." This quote from the 2022 ASBMR Task Force report represents the clearest clinical operationalization of the FDA's label language on treatment duration, and endocrinologists now routinely cite it when explaining annual reassessment to patients [9].

The Endocrine Society's 2019 Clinical Practice Guideline on pharmacological management of osteoporosis in postmenopausal women, which remains the most cited society guideline on the topic, recommends zoledronic acid as a first-line agent when oral bisphosphonate adherence is a concern, specifically because the once-yearly infusion format eliminates the gastrointestinal tolerability and dosing-window issues associated with oral formulations [11].

What Prescribers and Patients Need to Do Before Each Infusion

The checklist that follows synthesizes every monitoring requirement added between 2020 and 2024 into a single clinical protocol:

1. Order serum creatinine (and calculate eGFR via CKD-EPI) within 14 days before the infusion date.
2. Order serum 25-hydroxyvitamin D; if <20 ng/mL, prescribe ergocalciferol or cholecalciferol supplementation and reschedule infusion by at least 2 weeks.
3. Confirm serum calcium is in the normal range on the day of infusion or within 48 hours prior.
4. Ask about thigh and groin pain at every annual visit; if present, obtain plain film of femur before proceeding.
5. Review dental history; postpone infusion if invasive dental procedures are planned within 2 to 4 weeks (coordinate with dentist).
6. Confirm adequate hydration on the infusion day; advise the patient to drink at least 500 mL of water in the 2 hours before arrival.
7. Ask about new visual symptoms at every annual visit; refer to ophthalmology if uveitis or iritis is suspected.
8. Infuse over no less than 15 minutes using a separate vented infusion line; do not co-administer with calcium-containing IV solutions.
9. Monitor for post-infusion flu-like symptoms (fever, myalgia, headache) for 3 days; acetaminophen 1,000 mg every 6 to 8 hours as needed is recommended in the label for symptom management.
10. Document the infusion date and next planned infusion date in the chart and confirm drug holiday eligibility at year 3 (lower-risk) or year 6 (higher-risk) of therapy.

Generic Substitution and Biosimilar Considerations

Zoledronic acid 5 mg is a small-molecule drug, not a biologic, so it does not have biosimilars in the regulatory sense. It does have multiple FDA-approved generic versions. The FDA requires all ANDA holders to use the same Prescribing Information as Reclast (NDA 021,817) for safety-critical content, including the contraindication language and all warnings added between 2020 and 2024. Prescribers may substitute generics freely by therapeutic equivalence (rated "AB"), and patients should not notice a clinical difference between Reclast and approved generics when the drug is administered correctly.

One practical note: some hospital formularies stock the oncology formulation (Zometa, 4 mg/5 mL concentrate) and reconstitute it for osteoporosis use. This is an off-label practice associated with dosing error risk and is not endorsed by the current FDA label for either product. Pharmacists should verify that the correct formulation and concentration are prepared before dispensing.